Liraglutide Peptide (CAS 204656-20-2)

Liraglutide Peptide (NN2211) is a GLP-1 analogue modified with an amino acid substitution [Arg(34)→Lys(34)] and a C16 fatty acid chain at Lys26, which improve stability and extend its half-life (˜13 hours). The GLP-1 receptor agonist supports glucose-dependent glycemic control by enhancing insulin secretion and inhibiting glucagon release. Liraglutide also slows gastric emptying, reduces appetite, and promotes weight loss, making it effective for treating type 2 diabetes and obesity while lowering cardiovascular risk. It is the active ingredient in Victoza® and Saxenda®.

For research use only, do not use in humans!

Produced by JPT Peptide Technologies, a leader in custom peptide synthesis and diabetes reagents.

Liraglutide Peptide (CAS 204656-20-2) - Specifications

• Peptide sequence: H-HAEGTFTSDVSSYLEGQAA-Lys(Palmitoyl-gammaGlu)-EFIAWLVRGRG-OH
• Amount: 1.0 mg net (AAA)
• Purity: >95% (HPLC-MS)
• Counterion: TFA
• Delivery Format: Freeze-dried in plastic vial
• MW (average): 3751.24
• Application(s): Diabetes research
• Condition(s)/Topic(s): Diabetes
• Standard Delivery Time: 2-5 days
• CAS: 204656-20-2
• SMILES: N[C@@H](CC1=CNC=N1)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@@H](C)O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)O)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC)=O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC5=CNC6=C5C=CC=C6)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CO)=O)=O)=O)=O)CO)=O)=O)=O)=O)=O)=O)=O

Liraglutide Peptide’s Mechanism of Action

1) GLP-1 Receptor Agonism

Liraglutide peptide can bind to and activate glucagon-like peptide-1 (GLP-1) receptors that are widely distributed in tissues such as the brain, kidney, pancreas, gastrointestinal tract, and cardiovascular system. By mimicking the physiological action of endogenous GLP-1, it triggers a series of signaling pathways that help regulate both energy metabolism and glucose balance.

2) Blood Sugar Regulation

Within the pancreas, liraglutide boosts insulin secretion from β-cells in a glucose-dependent manner, ensuring insulin is released only when blood sugar levels rise. At the same time, it suppresses glucagon secretion from α-cells, which lowers hepatic glucose production. These combined actions contribute to smoother glycemic control and more stable blood sugar levels after meals.

3) Appetite and Satiety Effects

The GLP-1 receptor agonist additionally delays gastric emptying in the digestive tract, slowing nutrient absorption and helping to prevent sharp increases in blood glucose. In the central nervous system, particularly in the hypothalamus, it influences pathways that control appetite, decreasing hunger signals, limiting cravings, and promoting an earlier feeling of fullness. This coordinated effect between the gut and the brain helps lower calorie intake and supports weight loss over time.

4) Long-Lasting Action

Unlike endogenous GLP-1, which is rapidly broken down by the enzyme DPP-4, liraglutide can resist enzymatic degradation due to its structural modifications. These alterations enhance albumin binding, slow elimination, and extend circulation time, resulting in prolonged therapeutic activity and sustained receptor engagement.

Structure of Arg34Lys26-(N-epsilon;-(gamma;-Glu(N-alpha;-hexadecanoyl)))-GLP-1(7-37)

Liraglutide peptide shares about 97% sequence identity with human GLP-1 but contains specific modifications that improve its pharmacological stability and duration.

• At position 34, arginine is replaced by lysine [Arg(34)→Lys(34)], creating a reactive site for acylation and enhancing molecular stability.
• Additionally, the lysine at position 26 is linked to a C16 fatty acid chain via a glutamic acid spacer, which allows reversible albumin binding in the bloodstream. This interaction shields the modified peptide from DPP-4 degradation and slows clearance, extending its circulation time.

Together, these modifications give liraglutide peptide a half-life of about 13 hours, enabling once-daily dosing with sustained therapeutic levels.

JPT Peptide Technologies also offers customized variants tailored to your research needs. More information is available at our Custom Peptide Synthesis services.

Research Areas and Applications of Liraglutide Peptide (NN2211), CAS: 204656-20-2

• Obesity and weight management research: Investigated as an anti-obesity agent that promotes satiety, reduces appetite, and supports sustainable weight loss alongside dietary and lifestyle interventions (e.g., Saxenda®).
• Type 2 diabetes studies: Investigated for long-term glycemic control and clinical outcomes as a GLP-1-based antidiabetic therapy (e.g., Victoza®).
• Cardiometabolic research (hypertension, dyslipidemia, cardiovascular diseases): Investigated for its beneficial effects on blood pressure, lipid metabolism, and cardiovascular outcomes, including the reduction of major adverse cardiovascular events in patients with type 2 diabetes and obesity.
• Nonalcoholic Steatohepatitis (NASH) / Metabolic-Associated Steatohepatitis (MASH) studies: Investigated for improving liver steatosis, inflammation, and fibrosis in adults with obesity or type 2 diabetes-related fatty liver disease.
• Psychiatric and psychological safety research: Studied in pharmacovigilance trials to assess and manage reported psychiatric effects linked to GLP-1 receptor agonists, including liraglutide.
• Pediatric and special population investigations: Investigated for use in adolescents aged 12 years and older with obesity, and explored for managing obesity in individuals with severe mental illness.
• Renal and neuroprotection research: Studied for kidney-protective effects in diabetic nephropathy, as well as therapeutic potential in Alzheimer’s disease, Parkinson’s disease, and cognitive decline.
• Energy metabolism and endocrinology studies: Explored for regulation of systemic energy balance, hormonal pathways, and metabolic processes.
• Gut-brain axis investigations: Researched for its role in neuroendocrine signaling between the gut and brain, contributing to appetite regulation, reward-driven eating behavior, and energy balance.

Approved Liraglutide N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-Peptide Based Medications

Benefits of Liraglutide Peptide (NNC 90-1170), CAS: 204656-20-2

• Extended half-life (˜13hours) and enhanced stability: Structural alterations allow stronger albumin binding and resistance to DPP-4 degradation, slowing clearance and allowing convenient once-daily dosing with prolonged GLP-1 receptor activation compared to rapidly degraded native GLP-1.
• Broad therapeutic benefits: Beyond diabetes and obesity, studied for cardiovascular, renal, hepatic (NASH/MASH), and neuroprotective effects, supporting its role in systemic metabolic health.

Key Concepts

What is GLP-1 (Glucagon-like Peptide 1)?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced from the proglucagon gene and released by L-cells in the distal small intestine and colon following nutrient ingestion.

• It binds to GLP-1 receptors distributed across multiple tissues, including the pancreatic β-cells, gastric mucosa, kidneys, heart, and hypothalamus. Activation of these receptors enhances insulin secretion under hyperglycemic conditions, inhibits glucagon release, and delays gastric emptying, helping to regulate nutrient absorption.
• In addition, GLP-1 acts on the central nervous system to promote satiety and reduce food intake.

Collectively, these effects support glucose homeostasis, energy balance, and metabolic regulation. However, the native GLP-1 peptide has a very short half-life of approximately 1–2 minutes, as it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), which limits its direct therapeutic potential.

JPT’s Diabetes Peptide%3b GLP-1 receptor agonists

Glucagon-like Peptide 1 (GLP-1) and other GLP-1 receptor agonists have proven to be an effective treatment of Type 2 diabetes and obesity, offering significant benefits. They improve glycemic control by enhancing insulin secretion in response to elevated blood glucose levels; help reduce glucagon levels, further supporting blood sugar regulation; and slow gastric emptying, leading to weight loss, which is beneficial for diabetic patients who are obese. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.

• All peptides are made in Germany
• Bulk orders or custom peptide synthesis upon request
• Provision of freeze-dried aliquots for enhanced stability
• Proven track record
• Need the conjugated or modified peptide? Contact us!